Edgewise Therapeutics Inc (EWTX) FinancialsEWTXEdgewise Therapeutics Inc

Evaluating the bottom line, Edgewise Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -38.03%, provide a clear picture of how effectively EWTX converts its operational activities into shareholder value.

In the context of the broader market, EWTX competes directly with industry leaders such as ADPT and ABCL. With a market capitalization of $4.24B, it holds a significant position in the sector. When comparing efficiency, EWTX's gross margin of N/A stands against ADPT's 71.23% and ABCL's 100.00%. Such benchmarking helps identify whether Edgewise Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has reported consistent losses, with net income for Q2 2026 at -$57.3 million and an EPS of -0.53, indicating ongoing financial challenges.